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Abstract 
Most guanine nucleotide binding proteins (G-proteins) possess an S-prenylated C-terminal cysteine whose carboxyl group can be 
reversibly methylated. The prenylcysteine analog N-acetyl-S-geranylgeranyl-cysteine (AGGC) (50 /xM), a competitive inhibitor of 
prenylcysteine methyl transferases, introduced into streptolysin-O permeabilized HIT-T15 cells doubled the rate of basal (0.1 /xM Ca 2+) 
and of stimulated (10 p~M Ca 2+ or 100 /zM GTPyS) insulin secretion in a reversible and ATP-dependent manner. N-acetyl-S-farnesyl- 
cysteine (AFC) was less potent while N-acetyl-S-geranyl-cysteine was inactive. Prenylcysteine action on exocytosis did not involve 
inhibition of G-protein methylation, since (1) the methyl ester derivative of AFC, an inefficient inhibitor of methyltransferases in 
HIT-T15 cell fractions, was as potent as AGGC in stimulating exocytosis; (2) S-adenosyl-homocysteine, a general inhibitor of 
methylation reactions, did not alter basal or GTPyS-triggered secretion while inhibiting CaZ+-induced insulin release. The binding of 
G-proteins to Rab/GDP-dissociation inhibitor, Rab3A/GTPase activating protein or rabphilin-3A was not affected by the prenylcysteine 
analogs. AGGC or AFC had tile same effect on insulin release as a synthetic peptide mimicking the amino acid residues 52-67 of the 
G-protein Rab3A (Rab3AL). Moreover, the action on secretion of the combination of Rab3AL and prenylcysteines was not additive. We 
propose that the prenylcysteines and the Rab3AL peptide influence exocytosis by affecting the association of Rab3A with different 
proteins of the exocytotic machinery of insulin-secreting cells. 
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1. Introduction 
The moment-to-moment regulation of insulin secretion 
from pancreatic t-cells is the single most important factor 
Abbreviations: AFC, N-acetyl-S-trans, trans-farnesyl-L-cysteine; 
AFCME, AFC methyl ester; AGC, N-acetyl-S-trans-geranyl-L-cysteine; 
AGGC, N-acetyl-S-all-trans-gerzalylgeranyl-L-cysteine; FTA, S-trans, 
trans-farnesylthioacetic ac d; FTP, S-trans, trans-farnesyl-3-thiopropionic 
acid; GGTA, S-all-trans-geranylgeranylthioacetic acid; GGTP, S-all- 
trans-geranylgeranyl-3-thiopropionic acid; G-protein, guanine nucleotide 
binding protein; REEP, Rab exocytotic effector protein; SAH, S-adeno- 
syl-L-homocysteine; SAM, S-adenosyl-L-methionine; SL-O, streptolysin- 
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in the achievement of blood glucose homeostasis [1]. The 
mechanisms controlling the movement of insulin-contain- 
ing secretory granules from the Golgi apparatus toward the 
cell surface and their fusion with the plasma membrane 
remain to be defined. Studies performed in mammalian 
model systems as well as in yeast have revealed the 
involvement of guanine nucleotide binding regulatory pro- 
teins (G-proteins) in the targeting of the secretory vesicles 
to the appropriate acceptor membrane [2,3]. Evidence from 
mammalian systems favouring this idea includes the use of 
a synthetic peptide (Rab3AL) corresponding to the puta- 
tive effector binding domain of the small molecular mass 
G-protein (small G-protein) Rab3A, introduced into cells 
by microinjection or by streptolysin-O permeabilization. 
The peptide was shown to enhance secretion in mast cells 
[4], pancreatic acini [5], chromaffin cells [6] and insulin- 
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secreting cells [7,8]. The mechanism of action of Rab3AL 
is not fully elucidated. Recently, however, the peptide has 
been shown to interact with two proteins, REEP-I and 
REEP-2 (for Rab exocytotic effector proteins) that are 
released into the cytosol of insulin-secreting cells upon 
stimulation of exocytosis [8]. Thus, REEP-1, REEP-2 and 
Rab3A may be associated in a membrane-bound pre-fusion 
complex controlling exocytosis. The Rab3AL peptide 
would enhance insulin release by causing the dissociation 
of Rab3A from REEP-1 and REEP-2 [8]. 
The y subunits of heterotrimeric G-proteins and most of 
the small G-proteins have a characteristic carboxy-terminal 
sequence (CAAX, CXC or CC, where C = cysteine, A = 
aliphatic amino acid and X = any amino acid) that is 
post-translationally processed [2,9-11 ]. The modifications 
that these proteins undergo include the introduction, by 
specific prenyl transferases, of a farnesyl (C15) or a ger- 
anylgeranyl (C20) group in thioether linkage to the C- 
terminal cysteine. The carboxyl group of the cysteine is 
then methylated in a reaction that requires S-adenosyl- 
methionine as a methyl donor [12]. For the proteins ending 
with a CAAX sequence, the methylation reaction occurs 
after removal of the last three amino acid by proteolytic 
cleavage [9-12]. Prenylation and methylation ot only 
increase the hydrophobicity of the proteins, but have also 
been demonstrated to mediate protein-protein i teractions 
[13]. Thus, protein prenylation is required for the interac- 
tion between c~ and /3y subunits of transducin [14], be- 
tween Ras and adenylyl cyclase [15,16] and between Ras 
and the Ras-dependent ERK kinase stimulator [17]. In 
addition, post-translational modifications of small G-pro- 
teins are essential for their interaction with several regula- 
tory proteins [18-22]. The carboxy terminal methylation of 
G-proteins may play an important role in signal transduc- 
tion since, in contrast o isoprenylation, the process is 
reversible [ 12,23]. 
Glucose-stimulated insulin release from rat pancreatic 
islets has been shown to be diminished in the presence of 
3-deaza-adenosine and homocysteine [24]. The combina- 
tion of these drugs generates, inside the cells, S-adenosyl- 
homocysteine (SAH), a general inhibitor of methyl trans- 
ferases [25]. The observed inhibition suggests the involve- 
ment of a methyl acceptor site in the control of exocytosis. 
In contrast o SAH, prenylcysteine analogs such as S- 
acetyl-farnesyl-cysteine (AFC) are competitive substrates 
for carboxy-methyl transferases [26,27] and have been 
used to study the involvement of methylation of C-termi- 
nal cysteines in receptor-coupled vents [28-30]. It was 
also reported that AFC has a dual effect on insulin secre- 
tion from pancreatic islets, inhibiting glucose-induced se- 
cretion and stimulating secretion induced by agents thought 
to act directly on exocytosis [31]. 
In this study, we compared the effects on insulin exocy- 
tosis of prenylcysteine analogs with those of the Rab3AL 
peptide that mimics the amino acid residues 52-67 of the 
G-protein Rab3A. We propose that both the prenylcys- 
teines and the Rab3AL peptide stimulate insulin secretion 
by affecting the interaction of Rab3A with a protein 
complex controlling exocytosis. 
2. Materials and methods 
2.1. Materials 
Rab3A and Rab/GDI were purified from bovine brain 
membranes and cytosol respectively [32,33]. Rab3A/GAP 
was partially purified from rat brain cytosol [34]. The 
N-terminal fragment of rabphilin-3A (1-280 amino acids) 
was produced in E. coli as glutathione-S-transferase-fusion 
protein and purified as described [35]. The different 
prenylcysteine analogs were synthesized as previously de- 
scribed [28] and dissolved in water at a concentration f 25 
mM. AFCME, insoluble in water, was dissolved in 
dimethylsulfoxide at 25 mM. The Rab3AL peptide 
(VSALGIDFKVKTIYRN) was provided by Dr. W.E. 
Balch, Scripps Research Institute, La Jolla, USA. [a- 
32p]GTP and S-adenosyl-[3H-methyl]L-methionine (SAM) 
were purchased from Amersham (Bucks, UK). [ 35 S]GTPT S 
was from Du Pont-New England Nuclear (St. Louis, USA). 
S-adenosyl-homocysteine was obtained from Boehringer 
(Mannheim, Germany). Streptolysin-O was from Well- 
come (Basel, Switzerland). 
2.2. Cells 
HIT-T15 cells (passages 71-79) were cultured in RPMI 
1640 medium supplemented with 100 nM selenic acid, 33 
/zM glutathione and 10% fetal calf serum [36]. 
2.3. Insulin secretion from streptolysin-O permeabilized 
cells 
HIT-T15 cells were cultured for 2 days in microtiter 
plates (105 cells/well). The day of the experiment the 
cells were washed twice with a Ca2+-free modified Krebs- 
Ringer bicarbonate solution [36] and permeabilized for 5 
min at 37°C with 1.5 units/ml of streptolysin-O dissolved 
in buffer G (20 mM Hepes [pH 7.0], 140 mM potassium 
glutamate, 5 mM NaCI, 7 mM MgSO 4, 5 mM Na2ATP 
10.2 mM EGTA and sufficient CaCI 2 to achieve a free 
Ca 2+ concentration of 100 nM). The permeabilization 
medium was then replaced for a preincubation period of 5 
min by buffer G containing the substances under study 
(prenylcysteine analogs, Rab3AL peptide or SAH). Insulin 
secretion was triggered by exposing the cells for a 5 min 
final incubation period to buffer G supplemented with 
GTPTS or with 10 /zM free Ca 2+ in the continuous 
presence of the substances to be analysed. The amount of 
insulin secreted into the medium during the last 5-min 
period was assessed by radioimmunoassay [37]. 
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2.4. Methylation assay 
HIT-T15 cells, grown in 55-cm 2 Petri dishes (approx. 
2 X 107 cells) were washed twice with KRB and homoge- 
nized by sonication (3 × 1 s) in buffer A: 10 mM Tris-HC1 
(pH 7.0), 1 mM EDTA, 5; mM MgSO 4, 0.1% (V/V) 
mercaptoethanol, 10 /zg/ml leupeptin, 2 /zg/ml aprotinin 
and 10% (W/V)  sucrose. The homogenate was cen- 
trifuged for 10 min at 1000 × g to discard debris and 
unbroken cells. The supernatant obtained was again cen- 
trifuged for 30 min at 1400,0 X g yielding a pellet (crude 
membranes) that was resuspended in buffer A and a 
supernatant (cytosol). Both fi'actions were frozen at - 20°C 
until use. The reaction mixture for the methylation assay 
contained in a final volume of 100 p~l: 100 mM 
NaH2PO4/Na2HPO 4 (pH 6.8), 1 mM EDTA, 100 /zM 
GTPTS, 2.5 /zCi SAM (15 Ci/mmol) 100 /xg of cytosol 
and 150/zg of the crude membrane fraction. Alternatively, 
cytosolic and membrane proteins were incubated in buffer 
G containing 100 nM or 10 ,~M free Ca 2+ in the presence 
or absence of 100 /xM GTPyS. After 1 h at 37°C the 
reaction was stopped by the addition of 15% (W/V) 
trichloroacetic acid. The proteins were then resolved by 
PAGE (13% acrylamide) and detected by fluorography 
after 1 week exposure of the films at - 70°C. 
20 mM Hepes/NaOH (pH 7.4) and 1 mM dithiothreitol. 
The glutathione-agarose beads were then washed three 
times with 1 ml of the same buffer. Then, [35S]GTPTS- 
Rab3A (2 pmol) was added to the agarose beads contain- 
ing the N-terminal fragment of rabphilin-3A and a second 
incubation was performed for 30 min at 4°C in 50 /zl 
containing 20 mM Hepes/NaOH at pH 7.4, 10 mM 
MgCI 2, 3 mM EDTA, 1 mM dithiothreitol and 0.06% 
CHAPS. The mixture was then layered on 200 /zl of 40% 
sucrose bed dissolved in 20 mM Hepes/NaOH (pH 7.4), 
10 mM MgC12, 3 mM EDTA, 1 mM dithiothreitol and 
0.06% CHAPS. The sample was centrifuged 30 s at 10000 
X g and the tube immediately frozen in liquid nitrogen. 
The radioactivity of the bottom tip of the tube was mea- 
sured by liquid scintillation counting. 
2.7. GTPase assay 
GTPase activity of Rab3A was assayed essentially as 
described [41]. 
3. Results 
3.1. Effect of prenylcysteine analogs on insulin secretion 
2.5. Remoual by Rab / GDI of small G-proteins from 
membranes 
The ability of Rab/GD]! to extract small G-proteins 
from membranes was tested using a previously described 
method [33,38]. Briefly, HIT-T15 cells were disrupted in 
buffer B: 20 mM Tris-HC1 (pH 7.5), 1 mM EDTA, 6 mM 
MgC12, 1 mM dithiothreitol, 10 /zg/ml leupeptin and 2 
/xg/ml aprotinin and the homogenate centrifuged on a 
discontinuous sucrose gradient (2 M/0.5 M) for 2 h at 
65 000 X g. 100 /xg of the membranes collected at the 2 
M/0.5 M interphase were incubated for 10 min at 32°C in 
buffer B containing 100 /zM GDP/3S in the presence or 
absence of prenylcysteine analogs. Purified Rab/GDI (4 
/zg, approximately 0.2 /zM) was then added and the tubes 
incubated for another 5-min period at 32°C. Soluble and 
membrane associated proteins were separated by centrif- 
ugation (2 h at 65000 X g) on 2 M/0.5 M discontinuous 
sucrose gradients. The soluble and the membrane-attached 
small G-proteins were detected using the GTP-overlay 
technique after PAGE and blotting to nitrocellulose mem- 
branes [39]. 
2.6. Binding of Rab3A to rabphilin-3A 
The binding of Rab3A to rabphilin-3A was assayed as 
described [35,40] with a slight modification. Briefly, glu- 
tathione-agarose b ads (20 ,td) were first incubated with 
the indicated amounts of the N-terminal fragment of 
rabphilin-3A for 2 h at 4°C in a mixture (40/zl) containing 
In order to study the possible involvement of carboxy 
terminal methylation of G-proteins in the control of exocy- 
tosis, several prenylcysteine analogs were introduced into 
HIT-T15 cells permeabilized with the bacterial toxin strep- 
tolysin-O (SL-O). After permeabilization, the cells were 
incubated for 5 min at basal Ca 2÷ (100 nM) in the 
presence or in the absence of the prenylcysteine analogs to 
be tested and thereafter stimulated with 100 ~M GTPTS 
or with 10 /zM Ca 2--. As previously reported [7,36], 
GTPT S caused a 2-fold increase in insulin secretion, while 
at 10 /~M Ca 2÷ the release of hormone was about 8-fold 
higher compared to basal (100 nM Ca 2+) (Fig. 1). Using 
this protocol, AGGC (50/~M) stimulated more than 2-fold 
basal insulin release and doubled CaZ+-and GTPyS-stimu- 
lated secretion (Fig. 1). N-acetyl-S-farnesyl-cysteine 
(AFC), at the same concentration as AGGC, was less 
effective and N-acetyl-S-geranyl-cysteine (AGC) was inac- 
tive (Fig. 1). Carboxyl methylated N-acetyl-S-farnesyl-cy- 
steine (AFCME) was more potent han AFC and was about 
equipotent with AGGC (Fig. 1). 
The effect of AGGC on secretion was apparent at 10 
/zM and at 25 /xM was half of that measured at 50 /xM 
(not shown). To avoid possible non-specific effects of 
AGGC, concentrations higher than 50 /zM were not used. 
Prenylcysteine action on basal or GTPyS-stimulated 
insulin secretion was ATP-dependent (not shown). Other 
charged lipid molecules uch as palmitic acid (50 /zM) or 
sodium dodecyl sulfate (10/xM) were unable to reproduce 
prenylcysteine action (not shown). The effect of AGGC on 
exocytosis was reversible (Fig. 2). Thus, after 5 min 
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Fig. 1. Effect of prenylcysteine analogs on insulin secretion in permeabi- 
lized HIT-T15 cells. HIT-T15 cells cultured in microtiter plates were 
permeabilized with SL-O and preincubated during 5 min at 37°C at 100 
nM Ca 2+ in the presence of the indicated prenylcysteine analogs (50 
/.tM). The cells were then incubated at 100 nM Ca 2+ (top panel), 100 nM 
Ca 2+ + 100 /zM GTPTS (middle panel) or 10/xM Ca 2+ (bottom panel). 
in the continuous presence of the prenylcysteine analog under study. 
AGGC, N-acetyl-S-all-trans-geranylgeranyl-L-cysteine; AFC, N-acetyl- 
S-trans, trans-famesyl-L-cysteine; AGC, N-acetyl-S-trans-geranyl-L-cy- 
steine; AFCME, AFC methyl ester; The amount of insulin released into 
the medium during the last 5 rain incubation period was determined by 
radioimmunoassay. The results are expressed as mean_+S.E. (4 repli- 
cates) of a typical experiment out of 5. 
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Fig. 2. Reversibility of the effect of the prenylcysteine d rivative AGGC 
on insulin secretion. HIT-T15 cells were permeabilized as in Fig. 1 and 
preincubated during 5 min at 37°C and at 100 nM Ca 2+ in the presence 
( + ) or absence ( - ) of AGGC (50 /xM). The medium was subsequently 
discarded and the cells incubated for another 5 min period at 100 nM 
Ca 2+ (open bars) or 100 nM Ca 2+ + 100 /xM GTPyS (hatched bars) in 
the presence ( + ) or absence ( - ) of AGGC. The figure shows the amount 
of insulin released into the medium during the last 5 min incubation 
period. The figure shows a typical experiment out of 3 and the results are 
expressed as mean __+ S.E. of 4 replicates. 
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Fig. 3. Effect of various prenylcysteine analogs on insulin secretion from 
permeabilized HIT-T15 cells. HIT-T15 cells were permeabilized with 
SL-O and preincubated and incubated at 100 nM Ca 2+ in the presence of 
the different prenylcysteine analogs (50 /xM) as described in Fig. 1. 
GGTA, S-all-trans-geranylgeranylthioacetic acid; GGTP, S-all-trans- 
geranylgeranyl-3-thiopropionic acid; FTA, S-trans, trans-farne- 
sylthioacetic acid; FTP, S-trans, trans-farnesyl-3-thiopropionic acid. The 
figure shows a typical experiment out of 3 and the results are expressed 
as mean -t- S.E. of 4 replicates. 
incubation in the presence of AGGC, HIT-T15 cells recov- 
ered their basal secretory rate following removal of the 
prenylcysteine analog (Fig. 2). In addition, 5 min preincu- 
bation with AGGC did not potentiate a subsequent s imula- 
tion with GTPyS in the absence of the prenylcysteine 
derivative (Fig. 2). Taken together these findings demon- 
strate that AGGC does not cause exocytosis via a non- 
specific, detergent-like effect on cellular membranes. 
Other geranylgeranyl and farnesyl cysteine derivatives 
have been shown to be excellent competitive substrates for 
methyl transferases [26,27]. Introduced into SL-O perme- 
abilized HIT-T15 cells, S-geranylgeranyl-thiopropionic 
acid (GGTP) and S-farnesyl-thiopropionic acid (FTP), at 
50 /zM, stimulated insulin release to the same extent as 
AGGC (Fig. 3). S-geranylgeranyl-thioacetic acid (GGTA) 
which inhibits carboxyl methyltransferases but is not a 
substrate for the enzyme caused enhancement of insulin 
release similar to AGGC (Fig. 3). In contrast, S-farnesyl- 
thioacetic acid (FTA) was less potent and, at 50 /zM, only 
slightly increased exocytosis (Fig. 3). 
3.2. Effect of prenylcysteine analogs on G-protein carboxyl 
methylation 
The results obtained using the different prenylcysteine 
analogs uggest that the effect on insulin secretion cannot 
be attributed to the inhibition of carboxyl methylation 
reactions. In fact, AFCME which is already methylated, is 
not a competitive substrate of methyl transferases. In addi- 
tion, FTA according to the K i reported in the literature 
[26,27] is expected to be at least as potent as FTP. AFCME, 
being a product of methyl transferases could still exert an 
inhibition via an alternative mechanism. We decided, 
therefore, to monitor directly G-protein methylation reac- 
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Fig. 4. Effect of prenylcysteine analogs on methylation of small G-pro- 
teins in HIT-T15 cell extracts. HIT-T15 cells were disrupted by sonica- 
tion and the homogenate centrifuged to yield a cytosolic and a crude 
membrane fraction as described in Section 2. Aliquots of cytosol (100 
/xg) and membranes (150/xg) were incubated uring l h at 37°C with 2.5 
/xCi of [ 3H]SAM in the presence of 50/xM of the prenylcysteine analogs 
indicated. At the end of the incubation the proteins were precipitated and 
resolved by PAGE. The labelled small G-proteins (23-25 kDa) were 
detected by fluorography after 1-2 weeks' exposure of the films and 
quantified by densitometric scanning of the bands. The results are ex- 
pressed as % of the labelling obtaJLned in the absence of prenylcysteine 
analogs and are means -I- S.E. of 3 independent experiments. 
tions in cytosolic and membrane extracts of HIT-TI5 cells. 
As shown in Fig. 4, AGGC ;and AFC at 50 /xM inhibit the 
carboxyl methylation of small G proteins. In contrast, 
AGC and AFCME, at the same concentration, were inac- 
tive. These results indicate: that prenylcysteine analogs 
stimulate insulin release by ~. mechanism independent from 
the inhibition of methyl transferases. 
3.3. Effect of S-adenosyl-homocysteine on insulin secretion 
3.4. Effect of prenylcysteine analogs on possible target 
proteins 
Prenylcysteine analogs mimic the carboxyl terminus of 
small G proteins. Protein prenylation has recently been 
proposed to mediate protein-protein i teractions rather 
than to facilitate protein-lipid interactions at membranes 
[13]. The Rab/GDP-dissociation inhibitor (Rab/GDI) in- 
teracts with the C-terminal portion of several small G 
proteins [20,38] and requires the correct isoprenylation of
the terminal cysteine [38,42]. A possible explanation for 
our results on insulin secretion could be that the prenylcys- 
teine analogs compete with the small G proteins for the 
interaction with Rab/GDI. This may result in an increase 
in the exchange of GTP for GDP and, therefore, in an 
increase in the amount of small G proteins in activated 
form. This hypothesis was tested by analysing the ability 
of Rab/GDI to form a complex with and to extract a 
number of small G proteins present in membrane fractions 
of HIT-T15 cells. As we reported previously [38], purified 
Rab/GDI (0.2 /~M) extracted several small G-proteins 
detectable in the membrane fraction using the GTP-overlay 
technique (Fig. 7). At 50 /zM AGGC could not interfere 
with Rab/GDI action (Fig. 7). Similar results were ob- 
tained with AFCME (not shown). This indicates that 
Rab/GDI is not the target of prenylcysteine analogs. To 
substantiate further this conclusion, we also analysed the 
proportion of small G proteins in soluble and membrane- 
bound form in permeabilized cells. This proportion should 
vary if the prenylcysteine analogs prevent the formation of 
the complex with Rab/GDI [33,38]. However, the distri- 
bution of the small G-proteins detectable by the GTP-over- 
lay technique was unchanged by the treatment of perme- 
A further argument against he implication of methyla- 
tion reactions in the mechanism of action of prenylcysteine 
analogs on insulin secretion is supported by experiments 
using SAH, a general inhibitor of methyl transferases. This 
compound, when added at 100 /xM to permeabilized HIT- 
T15 cells, inhibited Ca2+-induced secretion but was with- 
out effect under basal conditions or when exocytosis was 
stimulated by GTPTS (Fig. 5). This suggests a possible 
role for methylation reactions in Ca 2+ but not in GTPyS 
evoked secretion. In agreement with this hypothesis we 
observed that in extracts of HIT-T15 cells incubated at 
stimulatory Ca 2+ concentrations (10 /xM) the methylation 
of a 36 kDa protein was markedly increased (Fig. 6). By 
contrast, the methylation of this protein was not affected 
by the addition of GTPTS to the reaction mixture (Fig. 6). 
Although GGTP (50 /zM) prevented the labeling of the 
small G-proteins (23-25 kDa bands) and of the y subunit 
of the heterotrimeric G-proteins (6 kDa band), this prenyl- 
cysteine derivative was without effect on the methylation 
of the 36 kDa protein (Fig. 6). AFCME at the same 
concentration did not affect the methylation either of the 
G-proteins or of the 36 kDa protein (Fig. 6). 
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Fig. 5. Effect of S-adenosyl-homocysteine (SAH) on insulin secretion 
from permeabilized HIT-T15 cells. HIT-T15 cells were permeabilized 
with SL-O and preincubated for 5 rain at 100 nM Ca 2÷ in the presence 
(+)  or absence ( - )  of 100 /xM SAH. The medium was then replaced 
with 100 nM Ca 2+ (open bars), 100 nM Ca2++ 100 /xM GTPyS 
(hatched bars) or 10/xM Ca 2+ (filled bars) in the continuous presence or 
absence of SAH for another 5 min incubation. The figure shows the 
amount of insulin secreted uring the last 5 min of incubation period. The 
results are mean + S.E. (4 replicates) of a typical experiment out of 4. 
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Fig. 6. Effect of Ca z+ and GTPyS on protein methylation i HIT-T15 cell extracts. Aliquots of cytosol and membranes of HIT-T15 cells were incubated 
with 2.5 ~Ci [3H]SAM in glutamate buffer with 100 nM Ca 2+ (A), 100 nM Ca 2+ + 100 /xM GTPyS (B) or 10 /zM Ca 2+ (C-E) for 1 b as described in 
Section 2. GGTP and AFCME (50 /xM each) were included in the reaction mixture in lanes D and E, respectively. At the end of the incubation the 
proteins were resolved by PAGE and visualized by fluorography. The arrow indicates the position of the 36 kDa protein. The figure shows a typical 
experiment out of 3. 
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Fig. 7. Effect of AGGC on the ability of rab/GDI to extract small G-proteins from HIT-T15 cell membranes. HIT-T15 membranes were prepared as 
described in Section 2 and then incubated in the presence ( + ) or absence ( - )  of Rab/GDI (0.2 /xM) and AGGC (50 /xM). The proteins extracted by 
Rab/GDI were separated from those remaining attached to the membranes by centrifugation on a discontinuous sucrose gradient. Soluble and 
membrane-bound small G-proteins were detected by autoradiography using the GTP-overlay technique [39] after PAGE and blotting on nitrocellulose 
membrane. Similar results were obtained in 2 other independent experiments. 
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Fig. 8. Effect of prenylcysteine analogs on the binding of Rab3A to 
rabpbilin-3A. A fusion protein c(mtaining the N-terminal fragment of 
rabphilin-3A and bound to glutathione-agarose beads was incubated with 
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(filled square), AFC (open circle), AGC (open diamond) and AFCME 
(filled triangle). The mixture was then centrifuged and the amount of 
radioactivity remaining associated with the beads determined by liquid 
scintillation counting. The figure shows a representative experiment out 
of 3. 
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Fig. 9. Comparison between the effect of prenylcysteine analogs and of 
the Rab3AL peptide on insulin secretion. Top: HIT-T15 cells were 
permeabilized with SL-O and preincubated for 5 min with ( + ) or without 
( - )  50 /xM Rab3AL peptide at 100 nM Ca 2+. The medium was 
subsequently replaced with 100 nM Ca e+ (open bars), 100 nM Ca 2+ + 
100 /xM GTPTS (hatched bars) or 10/xM Ca 2+ (filled bars) in the 
continuous presence or absence of the peptide. The results are mean + S.E. 
(4 replicates) of the insulin secreted into the medium during the last 5 
min incubation of a typical experinaent out of 3. Bottom: After permeabi- 
lization with SL-O the cells were preincubated for 5 min and incubated 
for another 5 min period at 100 nM Ca 2+ with or without AGGC (50 
/.~M) (left panel) or AFC (50 /~M) (right panel) in the presence or 
absence of the Rab3AL peptide (50 /xM). C: control; G: AGGC; R: 
Rab3AL; F: AFC. The results how the amount of insulin secreted by the 
cells during the last 5 min incubation and are mean_+ S.E. (4 replicates) 
of a representative experiment out of 3. 
abilized HIT-T15 cells with 50/xM AGGC, AFC, AFCME 
and AGC (not shown). 
Rabphilin-3A, a Ca 2+ and phospholipid binding protein 
interacts with the GTP-liganded form of Rab3A [35,43,44]. 
We tested the effect of prenylcysteine d rivatives on the 
interaction between Rab3A and rabphilin-3A. As shown in 
Fig. 8, AGC, AFC and AFCME did not affect the binding 
of the small G-protein to rabphilin-3A. AGGC decreased 
the association between the two proteins but only at high 
concentrations (100 /zM). Taken together, these results 
indicate that the prenylcysteines are not stimulating exocy- 
tosis by preventing the interaction between Rab3A and 
rabphilin-3A. 
In SL-O permeabilized HIT-T15 cells a synthetic pep- 
tide (50 /zM) corresponding to the domain ranging from 
amino acid 52 to 67 of the small G proteins of the Rab3 
family (Rab3AL) augments both basal and stimulated in- 
sulin release in a similar manner to AGGC [7,8] (Fig. 9, 
top). We investigated the possibility that prenylcysteine 
analogs act on exocytosis at the same locus as the Rab3AL 
peptide. For this purpose the Rab3AL peptide was added 
together with AGGC or AFC. The effect on insulin secre- 
tion of the combination of these two types of compound 
was not additive (Fig. 9, bottom). The Rab3AL peptide has 
been postulated to prevent he interaction of small G-pro- 
teins of the Rab3 family with its GTPase activating protein 
(GAP) [4-7]. In contrast o these assumptions, we found 
that the peptide does not affect the interaction between 
purified Rab3A and purified GAP and also has no effect 
on the GDP/GTP exchange rate of the G-protein (not 
shown). As in the case of the peptide the prenylcysteine 
analogs neither affected the GTPase activity nor the gua- 
nine nucleotide xchange rate of Rab3A (not shown). 
4. Discussion 
The finding that a combination of 3-deaza-adenosine 
and homocysteine inhibits insulin secretion caused by 
agents raising cytosolic Ca 2+ suggested the involvement 
of a methylation reaction in the control of exocytosis [24]. 
This was based on the assumption that 3-deaza-adenosine 
and homocysteine, added together, would produce suffi- 
cient amounts of SAH inside the cells to inhibit methyla- 
tion reactions. In this study, using permeabilized cells, we 
could directly introduce SAH into HIT-T15 cells and 
demonstrate hat this maneuver does indeed inhibit Ca 2+ 
but not GTPTS-triggered secretion. Since SAH inhibits all 
enzymes using S-adenosyl-methionine as methyl donor, it 
remains to establish whether the methyl acceptor site 
involved in exocytosis is a protein or a phospholipid. 
However, in this study we have demonstrated that the 
methylation of a protein with an Mr of about 36 kDa 
increases during the incubation of HIT-T15 cell extracts at 
10 /zM Ca 2+. This protein is most probably the catalytic 
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subunit of protein phosphatase 2A that has the same Mr 
and is methylated atthe C-terminus in a reaction that is not 
inhibited by prenylcysteine analogs [45]. An increase in the 
methylation of the catalytic subunit of phosphatase 2A 
may change the activity of the enzyme and, in turn, 
stimulate xocytosis. This possibility requires further in- 
vestigation. 
The discovery that most G-proteins are methylated at 
the carboxyl group of the C-terminal cysteine [12] raised 
the possibility that this reversible post-translational modifi- 
cation plays a regulatory role in signal transduction. Sev- 
eral prenylcysteine analogs have been shown to act as 
competitive inhibitors for the enzyme methylating the car- 
boxy terminus of G-proteins and to inhibit receptor- 
agonist-mediated signal transduction i platelets [29] and 
neutrophils [30]. Here we demonstrate hat prenylcysteine 
analogs stimulate insulin secretion under basal conditions 
and potentiate secretion stimulated by Ca 2+ and GTPTS. 
However, our results indicate that prenylcysteine analogs 
act on exocytosis by a mechanism different from the 
inhibition of methyltransferases. Thus, as mentioned above, 
the general inhibitor of methyltransferases SAH does not 
stimulate insulin secretion under basal conditions or when 
the cells are stimulated by GTPyS and causes a decrease 
rather than an increase of Ca 2 +-induced secretion. In addi- 
tion, AFCME enhances insulin release despite the fact that, 
in HIT-T15 cell extracts, the compound was found to be an 
inefficient inhibitor of the carboxyl methylation of G-pro- 
teins. Prenylcysteine analogs were also found to inhibit 
basal and receptor-stimulated guanine nucleotide binding 
as well as GTP hydrolysis in membranes of the promyelo- 
cytic cell line HL-60 [46]. These effects were also not due 
to protein carboxyl methylation [46]. However, in the latter 
study, in contrast to the present work, AFCME was inef- 
fective. 
Several findings indicate that the results obtained with 
the prenylcysteine analogs are not due to non-specific 
toxic effects on the cells. First, the action of the prenylcys- 
teine analogs is ATP-dependent and the insulin released by 
these compounds depends on the rate of secretion, the 
response being less under basal than under stimulated 
conditions. The damage to secretory granules would in 
contrast result in a fixed increase in the amount of insulin 
present in the medium. Second, the rate of secretion 
returns to basal upon removal of AGGC, excluding the 
possibility of an irreversible ffect on the cells or on the 
intracellular organelles. Third, in contrast o all the other 
prenylcysteine analogs used in this study, AFCME is an 
uncharged molecule. In spite of this, it stimulates insulin 
secretion to the same extent as AGGC, indicating that the 
amphiphilic characteristic of most of the prenylcysteine 
analogs is not a prerequisite for their effect on exocytosis. 
In SL-O permeabilized cells, plasma membrane poten- 
tial, ion channels and receptor-mediated events are by- 
passed. This indicates that the site of action of prenylcys- 
teine analogs is located close to the exocytotic step. Pro- 
tein prenylation has been proposed to mediate protein-pro- 
tein interactions rather than protein-lipid associations [13]. 
Prenylcysteine analogs could, therefore, mimic the interac- 
tion between G-proteins and their targets. The regulatory 
protein Rab/GDI is known to bind to Rab3A and to other 
small G-proteins at their C-terminal domain [20]. For the 
interaction with Rab/GDI the isoprenylation but not the 
methylation of the C-terminus is required [42]. However, 
the failure of AGGC and AFCME to interfere with the 
ability of Rab/GDI to extract small G-proteins from mem- 
branes makes it unlikely that this regulatory protein is 
implemented in the action of the prenylcysteine analogs. 
Rabphilin-3A is a Ca 2 + and phospholipid binding pro- 
tein that associates with the GTP-liganded form of Rab3A 
and decreases the GAP-stimulated GTPase activity of the 
G-protein [35]. The interaction between these two proteins 
is thought o play a role in the control exocytosis since the 
hydrolysis of GTP appears to be required for exocytosis to 
occur [47,48]. The prenylcysteine analogs could decrease 
the interaction between Rab3A and rabphilin-3A and, in 
turn, cause an increase in exocytosis. However, most 
prenylcysteines that stimulate xocytosis have no effect on 
Rab3A-rabphilin-3A interaction and AGGC partially pre- 
vent the association of the two proteins only at high 
concentrations. Thus, rabphilin-3A is not the target of 
prenylcysteine action. 
A synthetic peptide mimicking the amino acid sequence 
52-67 of the small G-proteins of the Rab3 family 
(Rab3AL) has been shown to stimulate xocytosis in sev- 
eral secretory cell systems [4-6], including permeabilized 
insulin-secreting cells [7,8]. Several prenylcysteine analogs 
reproduce the effect of Rab3AL on exocytosis and the 
action of these compounds is not additive to that of the 
peptide. This suggests that the prenylcysteine analogs and 
Rab3AL act via a converging pathway. The Rab3AL pep- 
tide has originally been postulated to prevent he interac- 
tion of Rab3 with GAP, thereby increasing the time spent 
by the G-protein in an activated state [4-7]. However, our 
results, obtained with purified Rab3A, and the results 
reported by others using recombinant, unprenylated Rab3A 
[49], indicate that the mechanism of action of the peptide is 
different. In fact, the Rab3AL peptide does not affect 
Rab3A/GAP interaction. In addition, only one mutation in 
domain 52-67 of Rab3A was reported to curtail GAP- 
stimulated GTPase activity [50]. Olszewski et al. [8] have 
identified two proteins that specifically interact with the 
Rab3AL peptide in HIT-T15 cells. These proteins, called 
REEP-1 and REEP-2, are membrane-associated under basal 
conditions and are released into the cytosol upon stimula- 
tion of insulin release [8]. Thus, REEP-1 and REEP-2 may 
be part of a prefusion complex whose dissociation favors 
insulin release. Interestingly, several prenylcysteine analogs 
reproduce the effect of Rab3AL on exocytosis and the 
action of these compounds is not additive to that of the 
peptide. Therefore, prenylcysteine analogs and Rab3AL 
may act on the same pre-exocytotic fusion complex. Since 
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prenylcysteines mimic the C-terminal region of small G- 
proteins, it is unlikely that these compounds bind to REEPs 
at the same site as Rab3AL. However, prenylcysteines 
could affect the association between Rab3A and a compo- 
nent of the exocytotic fusion complex that interacts with 
the C-terminus of the small G-protein. In this case, both 
the Rab3AL peptide and ~the prenylcysteines would en- 
hance insulin release by binding to different proteins of the 
complex controlling exocytosis. 
In conclusion, the present findings clearly indicate that 
prenylcysteine derivatives act on exocytosis in a manner 
not related to protein methylation. The results are best 
explained by the interaction with a putative effector pro- 
tein which recognizes the prenylated C-terminus of small-G 
proteins and is a component of a complex controlling 
secretion. Future work will have to address the identity of 
this protein. 
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